PharmaMar announces the presentation of overall survival data from the OVA-301 trial with Yondelis + PLD in ovarian cancer at the 47th ASCO meeting

Madrid, 7 June 2011: Pharmamar, a biopharmaceutical company in Grupo Zeltia (ZEL.MC), announces the presentation of data showing the final results on progression free survival and overall survival (OS) from the OVA-301 trial at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, June 3-7.

In this large phase III randomised, multicentre trial first published in 2010 (Monk et. al, J Clin Oncol 28:3107-14, 2010), Yondelis® (trabectedin) in combination with pegylated liposomal doxorubicin (PLD) had already demonstrated an improved progression-free survival (PFS with 7.3 months (95% CI 5.9-7.9) Yondelis®+PLD versus 5.8 month PLD (95%CI 5.5-7.1), HR=0.79, p=0.019) and overall response rate (ORR with 27,6% versus 19%, p=0.008 ) in comparison to PLD alone as a second-line treatment in women with ovarian cancer that has progressed following initial treatment with platinum-based chemotherapy. These results were the basis for the EMA authorization for commercialization of Yondelis® in 2009 in Europe.

At ASCO, the final OS analysis (secondary endpoint), show an improvement in patients treated with Yondelis®+PLD, with a median OS of 22.2 vs 18.9 months for the combination vs single-agent PLD arms respectively (HR 0.86; p=0.0835). Statistical significance is achieved with P<0.05, however, in the multivariate analysis including all prognostic factors, specified in OVA_301 statistical plan, a p-value p=0.0285 statistically significant was achieved.

An exploratory analysis shows a consistent improvement in OS across all subgroups, and is more pronounced in the subgroup of patients relapsing 6-12 months after first line therapy, a very difficult-to-treat population as reported by Poveda A. et al. Ann Oncol 2010: 22(1): 39-48. In these patients with partially platinum sensitive (PPS) disease, Yondelis®+PLD has shown a median OS of 22.4 months versus 16.4 months, representing a 6-months advantage in survival relative to single-agent PLD (HR: 0.64, p=0.0027), being the longest OS data ever

The safety profile was consistent with previous published data.

Further the OVA-301 an additional analysis of the progression free survival data presented in a poster by Dr. Poveda confirms the previous reported PFS results in favour of the Yondelis®+PLD combination in all platinum sensitive treated patients. Both OS and PFS data is presented during the Gynaecologic Cancer Poster Session on Sunday, June 5th, 2011.

All results confirm the role of Yondelis®+PLD in the treatment of recurrent ovarian cancer as a non-platinum / non-taxane containing regimen for the platinum sensitive diseased patients.

**Other publications containing Yondelis® treatment presented are:**

At the poster discussion on Saturday on June 4th, 2011:

*Developmental therapeutics. Clinical pharmacology and immunotherapy Poster Session. A Phase I dose-finding study of trabectedin (T) in combination with cisplatin (C) in patients (pts) with advanced solid tumors. First author: C. Sessa*

At the session on Monday, June 6th, 2011:

*Breast Cancer Poster Session. Final results of a phase II trial of trabectedin (T) in triple-negative, HER2-positive and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts). First author. K. L. Tedesco*

Other Yondelis data in soft tissue sarcoma are available at the full session details for the 2011 Annual Meeting, which can be found through the ASCO ePlanner: http://apps.asco.org/ePlanner/am2011.aspx
According to the licensing agreement between PharmaMar – a subsidiary of Zeltia, S.A – and Centocor Ortho Biotech Products, L.P., PharmaMar will market Yondelis® in Europe (including Eastern Europe), and Centocor Ortho Biotech Products, L.P. has rights to market Yondelis® in the rest of the world, except Japan, a market where PharmaMar SA and Taiho Pharmaceutical CO., LTD. have a licensing agreement to develop and commercialize Yondelis®.

About PharmaMar
PharmaMar is Grupo Zeltia’s biotechnology subsidiary; it is a world leader in discovering, developing and selling marine-based drugs to treat cancer. Yondelis® is Spain’s first antitumour drug. Yondelis® is currently approved for STS in 33 countries outside the EEA, and in 10 of those countries for platinumsensitive ROC as well (including Brazil and Canada). Yondelis® is approved for STS and platinumsensitive ROC in all 30 countries of the EEA; in Switzerland it is approved for STS. Yondelis® is also undergoing Phase II trials on breast and paediatric cancers. PharmaMar has five other compounds in clinical development: Aplidin®, Irvalec®, Zalypsis®, PM01183 and PM060184. PharmaMar also has a rich pipeline of pre-clinical candidates and a major R&D programme.

About Zeltia
Zeltia S.A. is a world-leading biopharmaceutical company specialised in the development of marine-based drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Noscira, a biotech firm focused on discovering and developing new drugs against Alzheimer’s disease and otherneurodegenerative central nervous system diseases; Genómica, Spain’s leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two highly profitable companies that are leaders in their respective market segments.

Important note
PharmaMar, which is headquartered in Madrid (Spain), is a subsidiary of Grupo Zeltia (Spanish stock exchange: ZEL), which has been listed on the Spanish Stock Exchange since 1963 and on Spain’s Electronic Market since 1998. This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

For more information (Tel. +34 91 444 4500)
This note is also available at PharmaMar website: www.pharmamar.com and Zeltia website: www.zeltia.com